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OBJECTIVE: To describe nutritional status, body composition and lipid profile in children and adolescents receiving
protease inhibitors.
METHODS: Fifty-nine patients, 23 treated with protease inhibitors (group 1) and 36 not using protease inhibitors
(group 2). Their dietary intake, anthropometry, bioimpedance analysis and lipid profile variables were measured.
RESULTS: There was no difference in nutritional status or body composition between groups at the beginning of the
study. After 6 months of follow-up, there was an increase in weight and height in both groups, as well as in waist
circumference and subscapular skinfold thickness. In group 2, body mass index and triceps skinfold thickness
adequacy were significantly higher after 6 months of follow-up. The groups had similar energy and macronutrient
intake at any time point. After 6 months, group 1 had a higher cholesterol intake and group 2 had a higher fiber
intake. Triglyceride serum levels were significantly different between the groups, with higher values in G1, at any
time point [G1: 153 mg/dl (30–344); 138 (58–378) versus G2: 76 mg/dl (29–378); 76 (29–378)]. After 6 months of
follow-up, G1 had higher LDL-cholesterol than G2 [104 mg/dl (40–142) versus 82 (42–145)].
CONCLUSION: The use of protease inhibitors, per se, does not seem to significantly interfere with anthropometric
measures, body composition and food intake of HIV-infected children and adolescents. However, this antiretroviral
therapy was associated with a significant increase in triglyceride and LDL-cholesterol in our subjects.
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Highly active antiretroviral therapy (HAART) including
protease inhibitors (PI) has been associated with effective
and lasting reduction in HIV viral load, with a decreased
incidence of opportunistic infections and an improvement
in the survival, neurodevelopment, growth and quality of
life of infected children.1,2
Some studies have shown that the introduction of
HAART results in a significant catch-up in weight and
height without an increase in body mass index (BMI).1,3,4 A
report of 192 children showed that an increase in mean
weight z-scores to normal values was obtained after 48
weeks and an increase in mean height z-scores approached
normal values in 96 weeks after the initiation of HAART.3
Therefore, treatment that includes PI has a positive effect on
patients’ nutritional status, promoting an increase in fat
mass, fat-free mass and body cell mass.5
However, a number of adverse effects associated with
HAART, and particularly PI, such as lipodystrophy syn-
drome, hyperlipidemia and peripheral insulin resistance,
have been identified in adult and pediatric patients.5,6 HIV-
positive children and adolescents receiving PI may be less
nutritionally compromised, but may have more altered lipid
profiles compared with those receiving no PI.
The pediatric literature on this issue is relatively scarce,
especially in the Brazilian population. The aim of the
present study was to describe, at two time points, the body
composition, nutritional indicators, energy and nutrient
intake and lipid profile in two clinically stable groups of
HIV-positive children and adolescents using or not using PI.
METHODS AND MATERIALS
A descriptive longitudinal study was undertaken at the
pediatric HIV outpatient clinics of a school hospital. Fifty-
nine patients were recruited for the study and divided into
two groups: HIV-positive children and adolescents using PI
(group 1, n = 23) and HIV-positive children and adolescents
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not using PI (group 2, n = 36). Each group was assessed at
two time points, i.e., at the beginning of the study (M1) and
after 6 months of follow-up (M2). The subjects of this
study were randomly selected and were paired for age and
gender.
Inclusion criteria were as follows: the subjects should be
between 3 and 17 years of age, should have the ability to
complete anthropometry, should not be taking appetite
stimulants or undergoing enteral or parenteral nutrition
therapy and should be on stable treatment with HAART for
at least 3 months prior to the study. Exclusion criteria were
as follows: subjects who were smokers, pregnant, who had
been hospitalized or developed serious illness within the 3
months prior to the beginning of the study, and who had
chronic diseases such as diabetes mellitus, diarrhea, liver
disease, cystic fibrosis, pancreatitis and renal failure that
could interfere with the development of the child and his/
her nutritional status.
Age and gender data, clinical and immunological
characteristics, including lipid profile, current antiretroviral
therapy, CD4 cell count, viral load and CDC clinical stage,
were obtained from the medical records.7
Weight, height and waist circumference were assessed
according to Heymsfield et al.8 by a dietitian who was
trained to take all measurements. Reference data from the
World Health Organization/National Center for Health
Statistics/Center for Disease Control and Prevention were
used. Midarm circumference, subscapular skinfold and
triceps skinfold were measured to determine lean body
mass and fat mass. Fat-free mass and total body water were
estimated by bioelectrical impedance using an RJL
Bioelectric Impedance AnalyzerH (BIA 103-A; Detroit, MI,
USA).
Usual food diary for the last 3 months was assessed, and
intake of energy, macronutrients, fiber, cholesterol, vitamin
A and vitamin C was calculated with the DietWinH software
at the two time points studied. The Dietary Reference Intake
(DRI) was used to calculate the adequacy of nutrient intake.9
The criteria set forth in the guidelines for the prevention
of atherosclerosis in childhood and adolescents were used to
define abnormal lipid levels. Hypercholesterolemia was
defined as a total fasting cholesterol level .170 mg/dl and a
low-density lipoprotein cholesterol level .130 mg/dl.
Hypertriglyceridemia was defined as a fasting triglyceride
level .130 mg/dl.10 The non-high-density lipoprotein
(HDL)-cholesterol was calculated as the difference between
total cholesterol and HDL-cholesterol.11
The study was approved by the institutional ethics
committee, and all patients or their parents gave written
informed consent to participate after a detailed explanation
to each family.
STATISTICAL ANALYSES
Data are reported as median and range. The non-
parametric Mann–Whitney test was used to compare
variables with non-normal distribution. The x2 test or
Fisher exact test was used to compare frequency distribu-
tions across groups, and the Wilcoxon test was used for
longitudinal analysis. The level of significance was set at p,
0.05 in all analyses. Data were analyzed using the Statistical
Package for the Social SciencesH (SPSS) software, version
15.0.
RESULTS
The clinical and demographic characteristics of the
groups are described in Tables 1 and 2. All patients
recruited were clinically stable, and the clinical, immunolo-
gical and virology parameters did not differ significantly
between groups at any time point. The time of using
antiretroviral therapy was similar between groups
(PI = 51.45¡31.07; non-PI = 63.97¡36.84 months; p= 0.157).
Longitudinal analysis showed a significant difference in age
between the groups, as expected.
Anthropometric measurements and body composition
results, at the two time points, are described in Table 3.
After 6 months of monitoring, weight, height, waist
circumference and subscapular skinfold thickness were
significantly higher in both groups. Among subjects who
did not use PI, BMI and triceps skinfold thickness adequacy
were significantly higher after 6 months of monitoring.
HIV-positive children and adolescents had similar daily
energy intake and percentage of daily energy intake,
protein, fat and carbohydrates at the two time points.
After 6 months of monitoring, the group using PI had a
higher cholesterol intake, and the group not using PI had a
higher fiber intake. Both groups had a decrease in vitamin A
intake after 6 months of monitoring. Vitamin C intake was
lower after 6 months of monitoring only in the non-PI group
(Table 4).
Serum triglyceride levels and non-HDL-cholesterol levels
were significantly higher in the PI group compared with the
non-PI group, at any time point. The proportion of patients
with hypertriglyceridemia was significantly higher in the PI
group compared with the non-PI group at the two time
points (M1: PI 39% versus non-PI 2.7%; p= 0.0003; M2: PI
34.6% versus non-PI 8.3%; p= 0.01). Total cholesterol and
HDL-cholesterol did not differ significantly between
groups, whereas serum LDL–cholesterol levels were higher
in subjects using PI, but only after 6 months of follow-up
(Table 5).
DISCUSSION
In the present study, HIV-infected children and adoles-
cents presented similar anthropometric measurements, food
intake and body composition measurements regardless
of antiretroviral therapy. Serum triglyceride and LDL-
cholesterol levels were higher in the PI group than in the
non-PI group.
Over the last few years, numerous advances in antire-
troviral therapy have resulted in the improved survival and
nutritional status of individuals with HIV.2 Progress in the
treatment of AIDS has changed it into a chronic disease.
Clinical and immunological progression of the disease was
not observed in any of the subjects evaluated in the present
study.
In agreement with the results of Melvin et al.,12 children
and adolescents receiving PI therapy in the present study
had clinical characteristics consistent with more advanced
disease.
In this study, children and adolescents were similar
regarding nutritional status at the two time points. After
longitudinal analysis, a statistically significant increase in
BMI and triceps skinfold thickness was only observed in the
non-PI group. Studies have corroborated our results and
have shown nutritional status deterioration in children
using protease inhibitors. Dzwonek et al.13 found a
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reduction in body weight, BMI, mid-upper arm circumfer-
ence and subcutaneous fat in children using protease
inhibitors.
Fiore et al.5 and Melvin et al.12 did not find any
differences in body composition or in anthropometric
indices between groups using PI or not, the same as in the
present study. Some studies have shown gain in fat mass,
lean mass and body cell mass, whereas others have found
improvement in only one body compartment.4
Our results also suggest that the increase in waist
circumference and subscapular skinfold thickness after 6
months of follow-up in both groups of children and
adolescents may represent a predisposition to visceral fat
accumulation.14 Evaluation of alterations indicative of body
fat redistribution in HIV-positive children is known to be
difficult because of the changes in body composition that
are characteristic of childhood and adolescence, and also
because of the scarcity of reports in the literature.15
Bioelectrical impedance did not predict morphological
changes in the present study. Both groups had similar and
unchanged body composition. The applicability of the
bioelectrical impedance prediction equations for total body
water and for fat-free mass to children with specific medical
problems has been questioned.16 Other techniques could be
used to better characterize the redistribution of body fat,
including skinfold thickness measurements, the segmental
bioelectrical impedance technique, dual–energy X-ray
absorptiometry and magnetic resonance imaging.17
The energy and protein consumption of most children
and adolescents seemed to be adequate and was similar
between the two groups at the two time points. The results
are similar to those reported by Tremeschin et al.18 Miller
et al.,19 in a large prospective study, showed that stable
HIV-infected children receiving well over the recommended
dietary allowance (RDA) in total calories and protein still
had growth parameters below those found in the control
group.
Arpadi et al.16 suggested that the level of viral load could
influence the amount of lean mass and the food intake of
HIV-infected children. Thus, it is possible that viral load or
aspects of the immune response, as well as the production
of inflammatory cytokines, adversely affects the food intake
and growth of these individuals.
Sharma et al.20 analyzed dietary macronutrient intake in
HIV-infected children for 10 years, and observed that
energy intake exceeded the estimated energy requirement
(EER) for ideal body weight by 62% for males and 39% for
females in 1995; and in 2004, energy intake still remained
19% above the EER in both groups. They also found that
protein intake was nearly 400% of the RDA for ideal body
weight in 1995, and daily protein intake still exceeded the
RDA by 60% in both groups in 2004.
Both groups of HIV-infected children and adolescents
presented a low percentage of adequate fiber consumption
and, at time point 2, the patients not using PI increased fiber
consumption. Despite the apparent adequacy of vitamin A
intake in both groups, at both time points, there was a
statistically significant reduction in vitamin A intake after 6
months of follow-up. The same occurred with vitamin C
intake, but only in the non-PI group. These events should be
checked periodically in order to avoid subclinical deficiencies.
Although definitions of retinol deficiency vary across
studies, reports of retinol deficiency in preschool children
show rates up to 74.5% in Brazil, 30% in Argentina and 46%
in Mexico.21 This study supports the idea of poor intake as
the main cause for the high prevalence of retinol deficiency.22
Vitamin A deficiency is associated with exacerbation of
oxidative stress, decrease in CD4+ cells, increase in HIV-
related morbidities, accelerated disease progression owing to
greater activation of nuclear factor-kB and higher mortality.
Furthermore, HIV-infected patients seem to be particu-
larly vulnerable to nutritional deficiencies that impair
their already compromised immune function. These
Table 1 - Clinical and demographic characteristics of HIV-positive children and adolescents using and not using PI:
analysis between groups and longitudinal analysis.
Parameters G1 (PI) G2 (No IP)
M1 M2 M1 M2
Age (months) 114 (54–196) 121* (59–201) 110 (60–190) 118{ (66–195)
% Female 60.9 60.9 44.4 44.4
T-CD4+ lymphocyte count
(cell/mm3){
565 (74–1925) 613 (31–1983) 686.5 (240–1533) 727 (192–13.800)
Viral load (copies/ml){ 9474.5 (,50–47.088) 3329.5 (,50–282.247) 7846 (,50–96.886) 7600 (,50–160.069)
G1: group using PI; G2: group not using PI.
M1: initial moment; M2: final moment.
*Values were statistically different in the group of children and adolescents using PI (G1) after 6 months of follow-up: p , 0.05.
{Values were statistically different in the group of children and adolescents not using PI (G2) after 6 months of follow-up: p , 0.05.
{Values were not statistically different between groups of children and adolescents using and not using PI and in longitudinal analysis: p . 0.05.
Table 2 - Clinical category of HIV-positive children and
adolescents using and not using PI: analysis between
groups and longitudinal analysis.
Clinical
category* G1 (PI) G2 (No PI)
M1 M2 M1 M2




3 (13) 3 (13) 9 (25) 9 (25)
B: moderate
symptoms
5 (21.7) 4 (17.4) 9 (25) 9 (25)
C: severe
symptoms
15 (65.2) 16 (69.6) 18 (50) 18 (50)
G1: group using PI; G2: group not using PI.
M1: initial moment; M2: final moment.
*Values were not statistically different between groups of children and
adolescents using and not using PI and in longitudinal analysis: p . 0.05.
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susceptibilities might cause intracellular dysfunction in
some metabolic pathways, which in turn might inhibit
growth and impair the prognosis of the disease.23
Hyperlipidemia has been observed as early as a few
weeks after the introduction of PI in adult patients, and it is
a major concern because of its association with athero-
sclerosis. In fact, several recent case reports described
cardiovascular events in young patients taking PI and
showing high levels of total cholesterol and triglycerides in
the absence of other risk factors.24 But dyslipidemia in adult
HIV-positive patients can be controversial. Daminelli et al.25
found that an HIV-positive group had smaller cholesterol
and triglyceride concentrations than healthy control sub-
jects, and HDL-cholesterol was similar in both groups.
The results of our study showed that up to 23% of subjects
had abnormal lipid levels. The predominant lipid abnorm-
ality associated with PI treatment is hypertriglyceridemia.
This finding is similar to what has been demonstrated in
other studies in which individuals using PI had higher
triglyceride levels than those not using PI.5,6 Other studies
of HIV-infected adults treated with PI obtained the same
results.26,27
Several small cross-sectional studies have shown eleva-
tions in total cholesterol in HIV-infected children.6 In
contrast, in the present study, serum LDL-cholesterol levels
were increased after 6 months of monitoring in the PI group,
but these values were close to the normal levels recom-
mended, and might be a reflection of a higher cholesterol
intake after 6 months of monitoring. Chantry et al.,28
evaluating the lipid profile and glucose homeostasis in
HIV-positive children after initiating or changing antiretro-
viral therapy, found that 99% of the sample had higher
mean saturated fat intake than recommended levels and,
approximately one third of the children had a mean
cholesterol intake .300 mg.
Carter et al.,29 evaluating the cumulative risk of exposure
to HAART therapy and dyslipidemia, found that an
increased linear relationship between median cholesterol
and duration of first PI-inclusive regimen did not persist
after 24 months on the regimen. After 24 months, median
Table 3 - nthropometric measurements and body composition by bioelectrical impedance technique of HIV children and
adolescents using and not using PI: analysis between groups and longitudinal analysis.
Parameters* G1 (PI) G2 (No PI)
M1 M2 M1 M2
Weight (kg) 24.3 (15.6–48.9) 26.6{ (16.8–54.9) 26.05 (14.07–62.4) 27.8{ (15.8–61.8)
Height (cm) 129 (99–164) 131.5{ (102–166.5) 126.5 (101–159) 129.1{ (103–167.5)
BMI (kg/m2) 16.3 (13.3–19.7) 16.2 (12.7–19.8) 16.2 (13.5–24.7) 16.6{ (14.0–23.8)
Height/age adequacy (%) 94.3 (81.7–100.8) 95.9{ (81.2–101.8) 95.8 (87.8–109.4) 96.07 (84.9–104.3)
Weight/age adequacy (%) 90.90 (58.5–113.3) 89.4 (56.3–124.8) 90.7 (61.8–138.1) 91.1 (62.6–139.2)
Weight/height (%) 100 (81.1–113.5) 100.5 (77.4–123) 100.8 (81.1–135) 98.9 (79.0–146.7)
Waist circumference (cm) 59.5 (53–76) 62{ (52–76) 60 (50–81) 61{ (52.5–84.5)
Triceps skinfold thickness
(% adequacy)
72.7 (33.3–111.1) 81.8 (38.1–133.1) 77.7 (40–150) 79.8{ (51.8–108.9)
Subscapular skinfold thickness
(% adequacy)
100 (50–261.53) 111.1{ (53.3–369.2) 108.3 (38.4–228.5) 121.5{ (50–280)
Midarm circumference (cm) 15.4 (12.8–20.74) 15.3 (13.2–22.4) 15.8 (11.8–19.3) 16.1 (12.4–20.3)
Lean body mass (%) 79.7 (68.8–96.9) 79.4 (68.8–96.2) 83.6 (64–90.2) 82.6 (64.4–89.5)
Fat mass (%) 19.6 (3.06–31.1) 20.75 (3.82–31.2) 16.4 (9.9–30.5) 16.8 (10.3–35.5)
Total body water (%) 75.2 (69.6–88) 75 (70–81) 76.1 (70.1–88) 76.4 (68.8–79.1)
G1: group using PI; G2: group not using PI.
M1: initial moment; M2: final moment.
*Values were not statistically different between groups of children and adolescents using and not using PI: p . 0.05.
{Values were statistically different in the group of children and adolescents using PI (G1) after 6 months of follow-up: p , 0.05.
{Values were statistically different in the group of children and adolescents not using PI (G2) after 6 months of follow-up: p , 0.05.
Table 4 - nergy and nutrient intake of HIV-positive children and adolescents using and not using PI: analysis between
groups and longitudinal analysis.
Parameters* G1 (PI) G2 (No PI)
M1 M2 M1 M2
Energy (% adequacy) 130.12 (96.3–224.7) 134.1 (65.13–327.5) 119.3 (54.8–347.5) 136.1 (83.7–286.2)
Protein (% VET) 283.8 (144.1–538.2) 316.6 (110.3–159.5) 309.8 (88.7–834.6) 281.5 (122.7–1468)
Carbohydrate (% VET) 57.7 (31.3–69.6) 57.7 (46.1–67.7) 57.7 (43.3–223.9) 57.2 (36–298.8)
Fat (% VET) 25.6 (17.5–35.7) 25.4 (19.4–56.7) 25.3 (15.3–38.7) 25 (14.3–54.7)
Cholesterol (mg) 174.8 (115.1–360.6) 204.5{ (86.3–459) 164.6 (5.4–923.77) 194.5 (43.5–682.0)
Fiber (%) 68.4 (39.3–176) 87.4 (26.1–341.7) 70.1 (11.2–205.5) 81.1{ (33.7– 302.6)
Vitamin A (%) 141.6 (21.7–603.8) 112.16{ (21.4–545.4) 145.9 (9.51–128.06) 86.07{ (10.33–131.4)
Vitamin C (%) 209.4 (15.9–529) 135.1 (3.64–690.3) 198.7 (4.8–403.05) 112{ (958–175.6)
G1: group using PI; G2: group not using PI.
M1: initial moment; M2: final moment.
*Values were not statistically different between groups of children and adolescents using and not using PI: p . 0.05.
{Values were statistically different in the group of children and adolescents using PI (G1) after 6 months of follow-up: p , 0.05.
{Values were statistically different in the group of children and adolescents not using PI (G2) after 6 months of follow-up: p , 0.05.
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cholesterol remained fairly constant. Although HDL-
cholesterol has not been frequently measured in HIV-
infected children, Beregszaszi et al.30 found a significant
proportion of children (19%) with low HDL-cholesterol
values. The present study failed to demonstrate abnormal
serum levels of HDL-cholesterol.
Some studies have shown that the dyslipidemia might
reflect a subclinical alteration in adipose tissue and may
allow the detection of patients who are at risk of developing
lipodystrophy.31,32 Cheseaux et al.33 concluded that HIV-
infected children treated with HAART had some elevation
in their cholesterol similar to that seen in patients hetero-
zygous for familial hypercholesterolemia, and therefore
have a similar risk for premature atherosclerotic disease.
The non-HDL-cholesterol levels in the plasma correlate
directly with the risk of developing coronary artery disease.
McGill et al.34 showed an association between the concen-
trations of non-HDL-cholesterol and the extent of fatty
streaks in the abdominal aorta, right coronary artery and left
descending artery in adolescents and young adults.
Charakida et al.,35 with the purpose of determining the
impact of HIV infection and antiretroviral therapy on
markers of early vascular disease in children, showed that
HIV infection in childhood is associated with adverse
structural and functional vascular changes that are most
pronounced in children exposed to PI therapy. In this study,
triglycerides and non-HDL-cholesterol were higher in
PI-treated children compared with non-PI-treated and
untreated HIV-infected children.
Although the incidence of malnutrition in children with
HIV infection has decreased with HAART, a large number
of patients presented the side-effects of this therapy.
Dyslipidemia may develop early in children and adoles-
cents, seems to be associated with drug dosing and may be
more pronounced in children with higher PI levels.
A limitation of this study is that we did not assess the
pubertal status and physical abnormalities of lipodystrophy
because assessment of such abnormalities by physical
examination is inherently subjective and the results may
vary among different examiners.
CONCLUSIONS
In conclusion, it seems that the use of PI, per se, does not
significantly improve anthropometric measures, body com-
position and food intake of HIV-infected children and
adolescents. However, this antiretroviral therapy was
associated with a significant increase in triglyceride and
LDL-cholesterol levels in the subjects studied. Long-term
investigations with large samples need to be conducted not
only to ensure that the weight and height of these children
and adolescents can be maintained at the same rate as in
uninfected children, but also to evaluate the adverse effects
of PI use on lipid profile.
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